Vishal Kukreti

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

A. Keith Stewart, S. Vincent Rajkumar, Meletios Α. Dimopoulos et al. · New England Journal of Medicine · 2014 · 1.3K citations · Full text

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

David S. Siegel, Thomas G. Martin, Michael Wang et al. · Blood · 2012 · 654 citations · Full text

Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12

Michael Crump, John Kuruvilla, Stephen Couban et al. · Journal of Clinical Oncology · 2014 · 454 citations · Full text

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial

Craig B. Reeder, Donna Reece, Vishal Kukreti et al. · Leukemia · 2009 · 369 citations · Full text

Hematological Malignancy, Health Sciences, Medicine +8

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

Ravi Vij, Michael Wang, Jonathan L. Kaufman et al. · Blood · 2012 · 254 citations · Full text